Harrow (HROW) Cash from Operations Growth (1y) (2011 - 2026)
Harrow (HROW) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.83 Bn | 32.09 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.14 Bn | 20.99 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | 425.00% |
| 10 | Harrow | 1.41 Bn | 1.31 Bn | 27.05 Mn | -145.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -145.72% |
| Dec 31, 2025 | 147.31% |
| Sep 30, 2025 | 462.11% |
| Jun 30, 2025 | 70.76% |
| Mar 31, 2025 | 524.98% |
| Dec 31, 2024 | -304.45% |
| Sep 30, 2024 | 344.29% |
| Jun 30, 2024 | -160.14% |
| Mar 31, 2024 | 43.66% |
| Dec 31, 2023 | 334.27% |
| Sep 30, 2023 | -194.63% |
| Jun 30, 2023 | -6.05% |
| Mar 31, 2023 | -949.43% |
| Dec 31, 2022 | -149.13% |
| Sep 30, 2022 | 80.25% |
| Jun 30, 2022 | -10.66% |
| Mar 31, 2022 | -69.86% |
| Dec 31, 2021 | -163.25% |
| Sep 30, 2021 | -177.84% |
| Jun 30, 2021 | 305.21% |